709 related articles for article (PubMed ID: 29554940)
1. Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy.
Lin YH; Huang TL; Chien CY; Chen HC; Hsu HC; Huang EY; Wang CJ; Huang YJ; Wang YM; Huang CC; Chou SY; Liao KC; Fang FM
Radiat Oncol; 2018 Mar; 13(1):45. PubMed ID: 29554940
[TBL] [Abstract][Full Text] [Related]
2. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
[TBL] [Abstract][Full Text] [Related]
4. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
[TBL] [Abstract][Full Text] [Related]
5. Intensity-modulated radiation therapy achieves better local control compared to three-dimensional conformal radiation therapy for T4-stage nasopharyngeal carcinoma.
Chen JL; Huang YS; Kuo SH; Hong RL; Ko JY; Lou PJ; Wang CW
Oncotarget; 2017 Feb; 8(8):14068-14077. PubMed ID: 27764778
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of total tumor volume in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy.
Liang SB; Teng JJ; Hu XF; Yang XL; Luo M; Fang XN; Liu DS; Chen Y; Fu LW
BMC Cancer; 2017 Jul; 17(1):506. PubMed ID: 28754109
[TBL] [Abstract][Full Text] [Related]
7. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
Zhang L; Tang LQ; Chen QY; Liu H; Guo SS; Liu LT; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Shao JY; Sun Y; Ma J; Hong MH; Mai HQ
Oncotarget; 2016 Feb; 7(5):6221-30. PubMed ID: 26716900
[TBL] [Abstract][Full Text] [Related]
8. Combined prognostic value of pretreatment anemia and cervical node necrosis in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: A large-scale retrospective study.
Zhang LL; Zhou GQ; Li YY; Tang LL; Mao YP; Lin AH; Ma J; Qi ZY; Sun Y
Cancer Med; 2017 Dec; 6(12):2822-2831. PubMed ID: 29034992
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma.
Lertbutsayanukul C; Prayongrat A; Kannarunimit D; Chakkabat C; Netsawang B; Kitpanit S
Strahlenther Onkol; 2018 May; 194(5):375-385. PubMed ID: 29302704
[TBL] [Abstract][Full Text] [Related]
10. Cigarette smoking complements the prognostic value of baseline plasma Epstein-Barr virus deoxyribonucleic acid in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy: a large-scale retrospective cohort study.
Lv JW; Chen YP; Zhou GQ; Tang LL; Mao YP; Li WF; Guo R; Lin AH; Ma J; Sun Y
Oncotarget; 2016 Mar; 7(13):16806-17. PubMed ID: 26919237
[TBL] [Abstract][Full Text] [Related]
11. Reirradiation with intensity-modulated radiotherapy for locally recurrent T3 to T4 nasopharyngeal carcinoma.
Chan OS; Sze HC; Lee MC; Chan LL; Chang AT; Lee SW; Hung WM; Lee AW; Ng WT
Head Neck; 2017 Mar; 39(3):533-540. PubMed ID: 27898191
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value and predictive threshold of tumor volume for patients with locally advanced nasopharyngeal carcinoma receiving intensity-modulated radiotherapy.
He YX; Wang Y; Cao PF; Shen L; Zhao YJ; Zhang ZJ; Chen DM; Yang TB; Huang XQ; Qin Z; Dai YY; Shen LF
Chin J Cancer; 2016 Nov; 35(1):96. PubMed ID: 27852284
[TBL] [Abstract][Full Text] [Related]
13. PET/CT-guided dose-painting versus CT-based intensity modulated radiation therapy in locoregional advanced nasopharyngeal carcinoma.
Liu F; Xi XP; Wang H; Han YQ; Xiao F; Hu Y; He Q; Zhang L; Xiao Q; Liu L; Luo L; Li Y; Mo Y; Ma HZ
Radiat Oncol; 2017 Jan; 12(1):15. PubMed ID: 28587681
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities.
Sun X; Su S; Chen C; Han F; Zhao C; Xiao W; Deng X; Huang S; Lin C; Lu T
Radiother Oncol; 2014 Mar; 110(3):398-403. PubMed ID: 24231245
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Correlations between ABO Blood Group and Pre-Treatment Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy.
Peng H; Chen L; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
PLoS One; 2016; 11(11):e0166194. PubMed ID: 27835689
[TBL] [Abstract][Full Text] [Related]
16. A retrospective study comparing the outcomes and toxicities of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy for the treatment of children and adolescent nasopharyngeal carcinoma.
Qiu WZ; Peng XS; Xia HQ; Huang PY; Guo X; Cao KJ
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1563-1572. PubMed ID: 28342002
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome and late toxicities of simultaneous integrated boost-intensity modulated radiotherapy in pediatric and adolescent nasopharyngeal carcinoma.
Tao CJ; Liu X; Tang LL; Mao YP; Chen L; Li WF; Yu XL; Liu LZ; Zhang R; Lin AH; Ma J; Sun Y
Chin J Cancer; 2013 Oct; 32(10):525-32. PubMed ID: 24016394
[TBL] [Abstract][Full Text] [Related]
18. Post-treatment serum lactic dehydrogenase as a predictive indicator for distant metastasis and survival of patients with nasopharyngeal carcinoma.
Wang J; Li L; Dong BQ; Xu YJ; Zheng YD; Sun ZW; Yang Y; Chen YY; Chen XZ; Chen M
Oncotarget; 2016 May; 7(19):27458-67. PubMed ID: 27050275
[TBL] [Abstract][Full Text] [Related]
19. Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study.
Chen QY; Guo SY; Tang LQ; Lu TY; Chen BL; Zhong QY; Zou MS; Tang QN; Chen WH; Guo SS; Liu LT; Li Y; Guo L; Mo HY; Sun R; Luo DH; Zhao C; Cao KJ; Qian CN; Guo X; Zeng MS; Mai HQ
Cancer Res Treat; 2018 Jul; 50(3):861-871. PubMed ID: 28903550
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Impact of Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation Therapy.
Peng H; Guo R; Chen L; Zhang Y; Li WF; Mao YP; Sun Y; Zhang F; Liu LZ; Lin AH; Ma J
Sci Rep; 2016 Feb; 6():22000. PubMed ID: 26924234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
